Guo Ming, Yasheng pharmaceutical: China's pharmaceutical innovation ushers in a golden age of favorable time, favorable place and harmonious people!

On May 12, 2017, the summit of future leaders of China's pharmaceutical industry was held in Beijing At the meeting, Guo Ming, general manager of Yasheng pharmaceutical, expressed his views on the form and process of China's new drug development He said that China's new drug research and development has entered a golden age, and that time, place, people and harmony have brought infinite possibilities to the industry In his opinion, for pharmaceutical innovation enterprises, "the leftovers are the king" Only by enduring loneliness and sticking to the end, can they enjoy the scenery when spring comes, "otherwise, when spring comes, you will not be the fertilizer under the flowers and trees." Four years ago, Guo Ming was very optimistic about the future of China's new drug research and development But he also admitted that there are problems in all aspects, including basic research and development, technical environment, regulatory environment and integrity system There are many obstacles in making innovative drugs in China But these obstacles did not scare Guo Ming and Yasheng away Yasheng pharmaceutical is the second venture of the same team In 2005, Guo Ming joined the entrepreneurial management team of asun biology in the United States In the same year, he co founded the new drug R & D center of asun (Shanghai), a wholly-owned subsidiary company in Shanghai This is one of the first domestic institutions to target new anti-cancer drugs based on new targets, and also one of the pioneers to obtain the clinical trial batch number of small molecule new drugs of FDA by using domestic laboratory data In 2009, due to the financial crisis, asun biology stopped operation Guo Ming and two founders of asun, Yang Dajun and Wang shaomeng, led the asun (Shanghai) team to establish a new company, named "asun", meaning the company's growth and prosperity Previous R & D projects of ASO have been sold, two of which have been transferred to Sanofi and Debu for hundreds of millions of dollars In August 2015, Yasheng pharmaceutical completed a round of financing of RMB 96 million; in December 2016, Yasheng pharmaceutical completed a round of financing of RMB 500 million In the process of the second start-up, the credit system, which is the most perplexing problem in drug innovation, is being solved from the top-level construction of the system Guo Ming pointed out that "drug clinical data verification" provides the possibility for the international competition of domestic innovative drugs, otherwise, "you say you are a new drug, but people don't believe that what's the use of your data?" The core team of Yasheng Pharmaceutical Co., Ltd is one of the first researchers in the field of research and development of new target small molecule inhibitors for dual channel regulation of apoptosis and autophagy in the world According to the public information, Yasheng pharmaceutical currently has 8 product pipelines, of which 5 are international original drugs with "first in class" potential and 3 are "best in class" potential, of which 6 are in phase I-II clinical development stage in China, the United States and Australia respectively, and 4 are cell wilting Two kinds of kinase inhibitors, including apoptosis and autophagy dual channel regulatory targets Bcl-2, IAP and MDM2-p53, as well as clinically proven mature targets ALK, BCR ABL and c-Met For a long time, due to the high uncertainty of the future of small molecular inhibitors and the difficulty of research and development, many drugs have been expected to be abandoned In April 2016, venetoclax (abt-199), the first Bcl-2 inhibitor to be listed in the world, was approved by FDA Before that, it was a 30-year study In the clinical evaluation process, the drug has been awarded three breakthrough therapies by the FDA Analysts predict that the future market capacity of the drug will be at least 3 billion US dollars As the only cancer drug R & D in China to do apoptosis pathway, AXA pharmaceutical bears huge risks and has unlimited development potential In December 2016, AXA pharmaceutical announced the completion of round B financing of RMB 500 million Led by the advanced manufacturing industry investment fund managed by SDIC Innovation Investment Management Co., Ltd (hereinafter referred to as "SDIC innovation"), new investors such as Shiyu capital, Qianlong investment, founder and hantou, and round a investors such as Yuanhe origin, Yuanming capital and Yifeng venture capital jointly contributed to complete the investment Lu Dazhong, general manager of SDIC innovation, said: "Yasheng pharmaceutical has made another major breakthrough in the field of new targets of apoptosis and autophagy dual channel regulation, which is the focus and highlight of this investment." Golden Age "but five years ago, it was very difficult to do innovative medicine in China and want to finance." Guo Ming said frankly that China's innovative drugs are short of history and scale, and many people are not very clear about the process of new drug research and development The success rate of a billion dollars, ten years and nine lives makes investors flinch They never thought that drug innovation is a process of creating value, and virtual intellectual property rights can be converted into real value Fortunately, now Chinese investors begin to have such a concept In the past five years, when many companies' projects are developed to determine the clinical candidates, some large companies will throw out olive branches and use tens of millions of dollars of down payment and hundreds of millions of dollars of milestone payment to realize the transfer of global intellectual property rights In this process, China's investor philosophy has been gradually reversed On the other hand, the attitude and actions of the government make everyone have a real sense of the importance of innovative drugs From the 11th five year plan to the 13th five year plan, the support for innovative drugs in three consecutive five-year plans is in place The government set up guiding funds, and the regional or private funds actively followed up From the autumn and winter of 2015, all kinds of capital went crazy, forming an outbreak period In 2016, cornerstone pharmaceutical received $150 million in round a investment, breaking the record of the largest round a investment of China's biopharmaceutical start-ups "Two years ago, it was still unthinkable." Guo Ming said so Although the policy is warm and the capital is warm, Guo Ming believes that the problem of too long clinical application of new drugs needs to be solved At present, China's clinical application has a long front line and many procedures It has to go through many levels of carpet inspection However, Guo Ming believes that the procedure of on-site inspection can be omitted, so that he can win several months to participate in international innovation competition earlier Because the purpose of supervision is to reduce the risk to the public, but the clinical phase I risk is completely controllable and should not be regulated in the same way as the listing, "otherwise, I've become an innovative drug in the United States and won't go in China for a year or two, how can I compete for innovative drugs internationally?"